/

Sociétés

En

Non vérifié

Enveda

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

13 communiqués de presse

Voir tous les communiqués de presse

23/07/2026

Multimédia

Événements

Industrie

Biotechnologie

Industrie pharmaceutique

Santé

Médecine - Divers

Enveda’s Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy; Additional Details to Be Shared at EADV

Source

Émetteur

1.00

0

15/04/2026

Marché du travail

Santé

Technique

Science

Industrie pharmaceutique

Biotechnologie

Enveda Appoints Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations

Source

Émetteur

1.00

0

31/03/2026

Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic Dermatitis

Source

Émetteur

1.00

0

23/12/2025

Science

Technique

Hygiène alimentaire

Médecine - Divers

Biotechnologie

Industrie pharmaceutique

Santé

Industrie

Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease

Source

Émetteur

1.00

0

17/12/2025

Marché du travail

Industrie

Science

Technique

Hygiène alimentaire

Médecine - Divers

Biotechnologie

Industrie pharmaceutique

Santé

Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy

Source

Émetteur

1.00

0

09/12/2025

Industrie

Hygiène alimentaire

Technologies de l'Information

Technique

Industrie pharmaceutique

Santé Publique

Biotechnologie

Médecine - Divers

Science

Logiciels

Santé

Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma

Source

Émetteur

1.00

0

04/09/2025

Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors

Source

Émetteur

1.00

0

28/05/2025

Technique

Biotechnologie

Santé

Santé Publique

Industrie pharmaceutique

Science

Technologies Diverses

Logiciels

Médecine - Divers

Industrie

Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis

Source

Émetteur

1.00

0

26/02/2025

Science

Technique

Médecine - Divers

Biotechnologie

Industrie pharmaceutique

Santé

Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M

Source

Émetteur

1.00

0

05/02/2025

Science

Biotechnologie

Industrie pharmaceutique

Santé

Technique

Médecine - Divers

Marché du travail

Industrie

Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0